Safety and Efficacy of Etanercept Monotherapy for Moderate-to-severe Plaque Psoriasis:A Prospective 12-week Follow-up Study
Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established...
Saved in:
Published in | Current medical science Vol. 37; no. 6; pp. 943 - 947 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Wuhan
Huazhong University of Science and Technology
01.12.2017
Department of Dermatology,Chinese PLA General Hospital,Medical College of Chinese PLA,Beijing100853,China%Department of Dermatology,Affiliated Hospital of Hebei United University,Medical College of Chinese PLA,Tangshan 063000,China |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established. This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy. These patients were treated with etanercept at a subcutaneous dose of 25 mg, twice a week, for 12 weeks. All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index(PASI) scores. At 4, 8, and 12 weeks after treatment, the response rates(PASI75) were 0%, 21.31%, and 40.98%, respectively. It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate-to-severe plaque psoriasis. |
---|---|
Bibliography: | Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established. This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy. These patients were treated with etanercept at a subcutaneous dose of 25 mg, twice a week, for 12 weeks. All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index(PASI) scores. At 4, 8, and 12 weeks after treatment, the response rates(PASI75) were 0%, 21.31%, and 40.98%, respectively. It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate-to-severe plaque psoriasis. Fang XIE , Rui WANG , Zi-gang ZHAO , Xian-fu MENG , Bi-wen LIN , Jie YANG , Wen-juan WANG , Xiang-yu DING , Yi YANG , Hua ZHAO , Cheng-xin LI, Heng-jin LI Yong ZHOU (1Department of Dermatology, Chinese PLA General Hospital, Medical College of Chinese PLA, Beijing100853, China 2Department of Dermatology, Affiliated Hospital of Hebei United University, Medical College of Chinese PLA, Tangshan 063000, China) 42-1679/R efficacy plaque psoriasis etanercept ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1672-0733 2096-5230 1993-1352 2523-899X |
DOI: | 10.1007/s11596-017-1832-7 |